垂体瘤的影像学进展。
Advances in the Imaging of Pituitary Tumors.
机构信息
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, National Institute for Health Research, Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.
Cambridge Endocrine Molecular Imaging Group, Metabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, National Institute for Health Research, Cambridge Biomedical Research Centre, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK; Department of Nuclear Medicine, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK.
出版信息
Endocrinol Metab Clin North Am. 2020 Sep;49(3):357-373. doi: 10.1016/j.ecl.2020.06.002. Epub 2020 Jul 15.
In most patients with pituitary adenomas magnetic resonance imaging (MRI) is essential to guide effective decision-making. T1- and T2-weighted sequences allow the majority of adenomas to be readily identified. Supplementary MR sequences (e.g. FLAIR; MR angiography) may also help inform surgery. However, in some patients MRI findings are 'negative' or equivocal (e.g. with failure to reliably identify a microadenoma or to distinguish postoperative change from residual/recurrent disease). Molecular imaging [e.g. C-methionine PET/CT coregistered with volumetric MRI (Met-PET/MR)] may allow accurate localisation of the site of de novo or persistent disease to guide definitive treatment (e.g. surgery or radiosurgery).
在大多数垂体腺瘤患者中，磁共振成像（MRI）对于指导有效的决策至关重要。T1 和 T2 加权序列可轻松识别大多数腺瘤。补充 MRI 序列（例如 FLAIR；磁共振血管造影）也有助于指导手术。但是，在某些患者中，MRI 检查结果为“阴性”或模棱两可（例如，无法可靠地识别微腺瘤或区分术后变化与残留/复发疾病）。分子成像[例如 C-蛋氨酸正电子发射断层扫描/计算机断层扫描（PET/CT）与容积 MRI 配准（Met-PET/MR）]可精确定位新发病灶或持续性疾病的部位，以指导确定性治疗（例如手术或放射手术）。
Zotero 插件